These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27377542)

  • 1. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.
    Huang G; Wharton W; Bhasin S; Harman SM; Pencina KM; Tsitouras P; Li Z; Hally KA; Asthana S; Storer TW; Basaria S
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):657-665. PubMed ID: 27377542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.
    Resnick SM; Matsumoto AM; Stephens-Shields AJ; Ellenberg SS; Gill TM; Shumaker SA; Pleasants DD; Barrett-Connor E; Bhasin S; Cauley JA; Cella D; Crandall JP; Cunningham GR; Ensrud KE; Farrar JT; Lewis CE; Molitch ME; Pahor M; Swerdloff RS; Cifelli D; Anton S; Basaria S; Diem SJ; Wang C; Hou X; Snyder PJ
    JAMA; 2017 Feb; 317(7):717-727. PubMed ID: 28241356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.
    Basaria S; Harman SM; Travison TG; Hodis H; Tsitouras P; Budoff M; Pencina KM; Vita J; Dzekov C; Mazer NA; Coviello AD; Knapp PE; Hally K; Pinjic E; Yan M; Storer TW; Bhasin S
    JAMA; 2015 Aug; 314(6):570-81. PubMed ID: 26262795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
    Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
    Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
    Wittert G; Bracken K; Robledo KP; Grossmann M; Yeap BB; Handelsman DJ; Stuckey B; Conway A; Inder W; McLachlan R; Allan C; Jesudason D; Fui MNT; Hague W; Jenkins A; Daniel M; Gebski V; Keech A
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):32-45. PubMed ID: 33338415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
    Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
    Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.
    Bhasin S; Ellenberg SS; Storer TW; Basaria S; Pahor M; Stephens-Shields AJ; Cauley JA; Ensrud KE; Farrar JT; Cella D; Matsumoto AM; Cunningham GR; Swerdloff RS; Wang C; Lewis CE; Molitch ME; Barrett-Connor E; Crandall JP; Hou X; Preston P; Cifelli D; Snyder PJ; Gill TM
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):879-890. PubMed ID: 30366567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
    Ngandu T; Lehtisalo J; Solomon A; Levälahti E; Ahtiluoto S; Antikainen R; Bäckman L; Hänninen T; Jula A; Laatikainen T; Lindström J; Mangialasche F; Paajanen T; Pajala S; Peltonen M; Rauramaa R; Stigsdotter-Neely A; Strandberg T; Tuomilehto J; Soininen H; Kivipelto M
    Lancet; 2015 Jun; 385(9984):2255-63. PubMed ID: 25771249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
    de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
    Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a Six-Month Multi-Ingredient Nutrition Supplement Intervention of Omega-3 Polyunsaturated Fatty Acids, vitamin D, Resveratrol, and Whey Protein on Cognitive Function in Older Adults: A Randomised, Double-Blind, Controlled Trial.
    Moran C; Scotto di Palumbo A; Bramham J; Moran A; Rooney B; De Vito G; Egan B
    J Prev Alzheimers Dis; 2018; 5(3):175-183. PubMed ID: 29972210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
    Emmelot-Vonk MH; Verhaar HJ; Nakhai Pour HR; Aleman A; Lock TM; Bosch JL; Grobbee DE; van der Schouw YT
    JAMA; 2008 Jan; 299(1):39-52. PubMed ID: 18167405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial.
    Spitzer M; Basaria S; Travison TG; Davda MN; Paley A; Cohen B; Mazer NA; Knapp PE; Hanka S; Lakshman KM; Ulloor J; Zhang A; Orwoll K; Eder R; Collins L; Mohammed N; Rosen RC; DeRogatis L; Bhasin S
    Ann Intern Med; 2012 Nov; 157(10):681-91. PubMed ID: 23165659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
    Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
    Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.